Members Only Content

Subscribe to get full access

Free Preview

Lead Advisor Manisha Samy sits down with the Senior Vice President of Corporate Strategy and Finance of Cellectis, Simon Harnest, to discuss the complexities of creating an allogeneic approach for developing CAR-T therapies, especially for solid tumors. Simon addresses why Cellectis is up for the challenge. He also addresses the discrepancy between current valuations of Cellectis and competitor, Moderna (MRNA) who happens to license from Cellectis.

related news & insights

  • January 10, 2025||0 min||||

    Coupang Deep Dive: January 2025

    CPNG Recommendation Jan 2025

  • an image of a man handing out hundred dollar bills
    January 7, 2025||0.2 min||||

    Dividend Hunting Season is Open

    If you love dividends, now's a good time to go hunting. Several companies -- some well known, others not -- [...]

  • January 9, 2025||1.3 min||||

    How to Update Your 7investing Preferred Payment Method

    Did you just get a new credit card or did your existing one expire? If so, this article is for [...]